Loss of 53BP1 causes PARP inhibitor resistance in BRCA1-mutated mouse mammary tumors

Janneke E. Jaspers¹,², Ariena Kersbergen¹, Ute Boon², Wendy Sol¹, Liesbeth van Deemter¹, Serge A. Zander¹, Rinske Drost², Ellen Wientjens², Jiuping Ji³, Amal Aly⁴, James H. Doroshow⁵, Aaron Cranston⁶#, Niall M.B. Martin⁶°, Alan Lau⁷, Mark J. O’Connor⁷, Shridar Ganesan⁴, Piet Borst¹, Jos Jonkers²*, Sven Rottenberg¹*

Authors’ affiliations
¹ Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; ² Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; ³ National Clinical Target Validation Laboratory, National Cancer Institute, Frederick, Maryland, USA; ⁴ Cancer Institute of New Jersey, New Brunswick, New Jersey, USA; ⁵ Division of Cancer Treatment and Diagnosis and Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland, USA; ⁶ KuDOS Pharmaceuticals, Cambridge, UK; ⁷ AstraZeneca, Macclesfield, UK; # Present address: Precos Ltd., In vivo services, Loughborough, UK; ° Present address: Mission Therapeutics, Cambridge, UK

Running title
53BP1 loss causes PARPi resistance in BRCA1-null tumors

Keywords
PARP inhibition, drug resistance, BRCA1, 53BP1, homologous recombination

Financial support
This work was supported by grants from the Netherlands Organization for Scientific Research (NWO-Toptalent 021.002.104 to J.E.J. and NWO-VIDI-91711302 to S.R.); the Dutch Cancer Society (grants 2006-3566 to P.B., S.R., J.Jo.; 2007-3772 to J.Jo., S.R., J. Schellens; 2009-4303 to S.R., J.Jo., P.B.; 2011-5220 to S.R., J.Jo.); the European Union (EU) FP6 Integrated Project 037665-CHEMORES (P.B., S.R.); the EU FP7 Project 260791-EurocanPlatform (J.Jo.); CTMM Breast Care (J.Jo., S.R.); and the NKI-AVL Cancer Systems Biology Centre (J.Jo.).

* Corresponding authors

Dr. Jos Jonkers
Div. of Molecular Pathology
Netherlands Cancer Institute
Plesmanlaan 121
1066 CX Amsterdam
The Netherlands
Phone: +31 20 512 2000
Fax: +31 20 669 1383
j.jonkers@nki.nl

Dr. Sven Rottenberg
Div. of Molecular Oncology
Netherlands Cancer Institute
Plesmanlaan 121
1066 CX Amsterdam
The Netherlands
Phone: +31 20 512 2082
Fax: +31 20 669 1383
s.rottenberg@nki.nl

Conflict of interest
A.C., N.M.B.M., A.L and M.J.O. were employees of KuDOS Pharmaceuticals, which developed olaparib and AZD2461. A.L. and M.J.O. are currently employees of AstraZeneca.

Word count: 5235

Figures: 7 (+ 10 Supplementary Figures and 2 Supplementary Tables)
Abstract

Inhibition of poly(ADP-ribose) polymerase (PARP) is a promising therapeutic strategy for homologous recombination-deficient tumors, such as BRCA1-associated cancers. We previously reported that BRCA1-deficient mouse mammary tumors may acquire resistance to the clinical PARP inhibitor (PARPi) olaparib through activation of the P-glycoprotein drug efflux transporter. Here we show that tumor-specific genetic inactivation of P-glycoprotein increases the long-term response of BRCA1-deficient mouse mammary tumors to olaparib, but these tumors eventually developed PARPi resistance. In a fraction of cases this is caused by partial restoration of homologous recombination due to somatic loss of 53BP1. Importantly, PARPi resistance was minimized by long-term treatment with the novel PARP inhibitor AZD2461, which is a poor P-glycoprotein substrate. Together, our data suggest that restoration of homologous recombination is an important mechanism for PARPi resistance in BRCA1-deficient mammary tumors and that the risk of relapse of BRCA1-deficient tumors can be effectively minimized by using optimized PARP inhibitors.
**Statement of significance**

In this study we show that loss of 53BP1 causes resistance to PARP inhibition in mouse mammary tumors that are deficient in BRCA1. We hypothesize that low expression or absence of 53BP1 also reduces the response of patients with BRCA1-deficient tumors to PARP inhibitors.
Introduction

Inhibition of poly (ADP-ribose) polymerase 1 (PARP1) induces synthetic lethality in cells that are defective in homologous recombination (HR) due to loss of BRCA1 or BRCA2 or other HR-associated genes (1-3). PARP1 inhibition results in unrepaired DNA single-strand breaks (SSBs), which are eventually converted into double strand breaks (DSBs) during DNA replication. Whereas HR-proficient cells can repair these DSBs in an error-free manner, HR-deficient cells cannot, and die. Preclinical studies and phase I and II clinical trials have demonstrated potent anti-tumor efficacy of the PARP inhibitor (PARPi) olaparib (AZD2281) as a single agent in BRCA1- or BRCA2-associated cancers with only modest side effects (4-10). Unfortunately, not all cancer patients carrying BRCA1 or BRCA2 mutations respond to PARPi therapy (4;10), which is impeding further clinical development of this promising therapeutic approach. Identification of the mechanisms underlying PARPi resistance is therefore important for improving treatment and for prediction of tumor response prior to treatment.

Since pre- or post-PARPi-treatment tumor samples from patients with BRCA1-deficient cancers are still limited, we studied the response and resistance to the clinical PARPi olaparib in a validated genetically engineered mouse model for BRCA1-mutated breast cancer (9;11;12). Mammary tumors that arise in these mice were highly sensitive to olaparib (9). Nevertheless, long-term olaparib response was frequently hampered by increased expression of the Mdr1a/b (also known as Abcb1a/b) genes, which encode the drug efflux transporter P-glycoprotein (Pgp) (9). Also the MRE11A-deficient human colon cancer cell line HCT-15, which expresses Pgp, could be sensitized to olaparib by combining it with the Pgp-inhibitor verapamil (13). However, the relevance of Pgp in clinical drug resistance is still controversial, and there may be a difference in the induction of Pgp expression between mice and humans (14).
Recently, we have also shown that mouse mammary tumors that contain the BRCA1<sup>C61G</sup> mutation still show hypomorphic BRCA1 activity that explains the modest responses to olaparib or cisplatin treatment (15). Using BRCA2-deficient cell lines, another PARPi resistance mechanism has previously been identified: genetic reversion of the BRCA2 mutation causes resistance to PARP inhibition or cisplatin (16;17). Secondary mutations that restore BRCA1/2 function have subsequently been found in platinum-resistant hereditary ovarian cancers (18;19).

Here, we set out to identify novel mechanisms of PARPi resistance that cannot be explained by Pgp-mediated drug efflux, residual BRCA1 activity or restoration of BRCA1 function. For this purpose we have used a mouse model, in which mammary tumors arise that contain a large, irreversible Brca1 mutation on a Pgp-deficient background. We report on inactivation of p53 binding protein 1 (53BP1) as a causal factor in PARPi resistance, and on the successful circumvention of drug resistance of Pgp-proficient tumors using AZD2461, a novel PARPi with lower affinity to Pgp.
Results

Elimination of Pgp prolongs the response of BRCA1-deficient mouse mammary tumors to olaparib, but tumors still develop drug resistance

Using the K14cre;Brca1^f/f;p53^f/f (KB1P) mouse model for BRCA1-associated breast cancer, we have previously shown that activation of Pgp induces resistance to the PARPi olaparib (9). To study olaparib sensitivity of KB1P mammary tumors in the absence of functional Pgp, we bred the Mdr1a/b null alleles (20;21) to homozygosity into our KB1P model (Supplementary Fig. S1A). Eleven individual mammary tumors from K14cre;Brca1^f/f;p53^f/f;Mdr1a/b^-/- (KB1PM) mice were orthotopically transplanted into syngeneic FVB mice, which were subsequently treated with olaparib and monitored for survival (Fig. 1A and Supplementary Fig. S1B). All tumors were initially highly sensitive to olaparib. Moreover, the response of tumors derived from the same original donor tumor was comparable (Supplementary Fig. S2), showing that initial heterogeneity in PARPi response is limited. The survival of mice bearing Pgp-deficient KB1PM tumors increased, compared with mice carrying Pgp-proficient KB1P tumors, following 28 days of treatment with olaparib (p = 0.0392, Fig. 1A and Supplementary Fig. S1B,C). This result confirms that Pgp plays a pivotal role in the development of olaparib resistance in the KB1P model, as we have shown previously using the Pgp inhibitor tariquidar (9). Despite this increased survival all mice eventually developed tumor recurrences that no longer responded to olaparib (Supplementary Fig. S1B). Due to the large intragenic deletion of Brca1 in our model (11), PARPi resistance can not be caused by restoration of BRCA function, as was found previously for BRCA2-deficient CAPAN1 cells (16). Hence, PARPi resistance can arise in vivo in the absence of two known resistance mechanisms: drug efflux by Pgp and genetic reversion of the Brca1 mutation.
The characteristics of olaparib-resistant KB1PM tumors suggest activation of DNA damage repair

We transplanted nine individual olaparib-resistant KB1PM tumors into syngeneic mice and found that the resistance was stable (Fig. 1B). To exclude that olaparib resistance in KB1PM tumors is driven by alterations of the drug target PARP resulting in restoration of poly(ADP-ribose) (PAR) formation, we tested the effects of olaparib on PARP activity in control versus olaparib-resistant tumors from three different donors (Fig. 1C). PAR levels were low or undetectable in olaparib-resistant tumors 30 minutes after olaparib administration and after 7 days of daily treatment with olaparib, showing that PARP function is still inhibited by olaparib, thus excluding alteration of the drug target as PARPi resistance mechanism. As a consequence of the inhibition of PARP activity in both control and olaparib-resistant tumors there is an increase in DNA DSBs, as measured by γH2AX staining (Supplementary Fig. S3).

To test whether the sensitivity to DNA damage inflicted by other DNA-targeting anti-cancer drugs would also be altered, we transplanted olaparib-resistant and corresponding control tumors from five individual KB1PM donors. The tumor-bearing mice were treated with the topoisomerase I inhibitor topotecan, the DNA adduct-forming agent cisplatin or the topoisomerase II inhibitor doxorubicin. Almost all drug-naive KB1PM tumors responded well to cisplatin or doxorubicin and about half of the tumors showed high topotecan sensitivity (Fig. 2A). In contrast, none of the olaparib-resistant KB1PM tumors shrunk more than 50% following treatment with topotecan (Fig. 2A,B). Although olaparib-resistant KB1PM tumors were usually still sensitive to cisplatin or doxorubicin, the time to relapse of these tumors was reduced in comparison to the drug-naive KB1PM tumors (Fig. 2C,D). The fact that olaparib-resistant KB1PM tumors are cross-resistant to topotecan and recover more quickly from cisplatin- or doxorubicin-mediated DNA damage supports the hypothesis that
olaparib-resistant KB1PM tumors have an altered DNA damage response compared
to control tumors.

**Loss of 53BP1 causes olaparib resistance by restoration of HR**

We and others have recently identified p53-binding protein 1 (53BP1) as a factor for maintaining the growth defect of Brca1-deficient cell lines (22;23). Loss of 53BP1 partially restores HR in Brca1-deficient cells, thereby reducing their hypersensitivity to PARP inhibition and DNA-damaging agents. Using immunohistochemistry we tested whether 53BP1 was lost in any of our KB1PM tumors which acquired olaparib resistance *in vivo*. We found that three out of 11 olaparib-resistant KB1PM tumors at least partly lost 53BP1 protein, whereas all untreated KB1PM tumors were positive (Fig. 3A,B). Besides these differences between individual olaparib-resistant tumors, we also observed intra-tumor heterogeneity: 53BP1-positive and –negative cell nests were both present in olaparib-resistant tumors KB1PM3 (Fig. 3B) and KB1PM8 (data not shown). In two olaparib-resistant KB1PM tumors we identified somatic mutations in the Trp53bp1 gene that explain loss of 53BP1 protein. We found two genomic rearrangements in olaparib-resistant KB1PM5 in intron 24 of Trp53bp1 (Supplementary Fig. S4A, B). By cDNA sequencing, however, we only detected a duplication of exons 25 and 26 (Fig. 3C and Supplementary Fig. S4C), indicating that the duplication of a part of exon and intron 24 leads to non-sense mediated mRNA decay. The duplication of exon 25 and 26 results in a frame shift and premature stop codon (Fig. 3C). In the 53BP1-negative tumor nests of the olaparib-resistant KB1PM8 we detected a heterozygous mutation in exon 12 (Fig. 3D). cDNA sequencing only showed the truncating mutation Q626*, suggesting that the wild-type allele is silenced, possibly by promoter methylation.

To test whether HR is restored in 53BP1-deficient KB1PM tumors, we derived cell lines from olaparib-sensitive and –resistant KB1PM5 tumors. The deletions of Brca1,
p53 and Mdr1 were confirmed by genotyping PCR (Supplementary Fig. S5A) and the array comparative genomic hybridization (aCGH) profiles of the cell lines resembled those of the original tumors (Supplementary Fig. S5B). Western Blotting confirmed the complete lack of 53BP1 in the resistant cells, whereas it was still present in sensitive KB1PM5 cells (Supplementary Fig. S5C). In a clonogenic assay the cell lines derived from the olaparib-resistant KB1PM5 tumor retained their resistance in vitro (Supplementary Fig. S5D). Importantly, we found that irradiation-induced RAD51 foci (IRIFs) were present in olaparib-resistant KB1PM5 tumor cells, but absent in olaparib-sensitive KB1PM5 cells, indicating that DNA repair by HR is restored in the 53BP1-deficient KB1PM tumors (Fig. 4A). However, the 53BP1-deficient KB1PM5 tumor cells did not contain as many RAD51 IRIFs as 53BP1- and BRCA1-proficient KP3.33 cells (Fig. 4B), suggesting that HR restoration by 53BP1 loss in KB1PM tumors is only partial, which may explain the lack of cross-resistance to cisplatin and doxorubicin. In addition to the cell lines we have analyzed the ability to form RAD51 IRIFs in short-term tumor cell cultures derived from 53BP1-negative olaparib-resistant KB1PM tumors and their controls (Fig. 4C). Olaparib-resistant tumor cells from KB1PM5 and 8 form RAD51 IRIFs and are negative for 53BP1 (Supplementary Fig. S6). Interestingly, olaparib-resistant tumor cells from the heterogeneous olaparib-resistant tumor KB1PM3 form RAD51 IRIFs, but also have functional 53BP1 in all cells tested, shown by the 53BP1 IRIFs. This indicates the presence of a 53BP1-independent mechanism of HR-restoration in the 53BP1-positive tumor cell nests. In addition to the KB1PM3, 5 and 8, we measured RAD51 and 53BP1 IRIFs in KB1PM1 and 9. Similar to KB1PM3, the olaparib-resistant cells of KB1PM9 form 53BP1 IRIFs, but also RAD51 IRIFs. Tumor cells derived from olaparib-resistant KB1PM1 have functional 53BP1 and do not show RAD51 IRIFs, indicating an HR-independent mechanism of PARPi resistance.
We next tested whether inactivation of 53BP1 is causal to PARPi resistance. To this end, we transduced two cell lines derived from an untreated KB1P tumor (KB1P-B11 and KB1P-G3) with lentiviral vectors encoding two individual short-hairpin RNAs (shRNAs) against Trp53bp1 (Fig. 5A). Also in these cell lines depletion of 53BP1 partially restored the formation of RAD51 IRIFs (Supplementary Fig. S7A). A decrease of 53BP1 indeed resulted in reduced sensitivity to olaparib (Fig. 5B), indicating that 53BP1 loss causes olaparib resistance. This notion was confirmed by experiments with the olaparib-resistant cell line KB1P-3.12 in which a point mutation in Trp53bp1 intron 22 leads to a cryptic splice acceptor site before exon 23 and production of a frame-shifted mRNA (Supplementary Fig. S7B). When we reconstituted functional 53BP1 in this cell line we observed increased olaparib sensitivity, further supporting the relevance of 53BP1 expression for olaparib sensitivity (Fig. 5C,D).

We also tested KB1P-B11 cells with stable shRNA-mediated depletion of 53BP1 in vivo after orthotopic transplantation of these cells in mice. The resulting outgrowths did not respond to olaparib anymore, whereas the controls were still sensitive (Fig. 5E). IHC analysis confirmed the complete loss of 53BP1 expression in tumors derived from KB1P-B11 cells with stable 53BP1 depletion (Supplementary Fig. S7C). This directly proves that absence of 53BP1 in KB1P tumors is sufficient for complete resistance to olaparib. In line with our cross-resistance experiments (Fig. 2C), all tumor cell line outgrowths responded well to cisplatin treatment, but 53BP1-negative outgrowths tended to relapse earlier (Fig. 5F).

In view of the complete cross-resistance of olaparib-resistant tumors to topotecan (Fig. 2A,B), we tested whether loss of 53BP1 also contributes to drug resistance of tumors that were only treated with topotecan. As the drug efflux transporter ABCG2 contributes to topotecan resistance of KB1P mouse mammary tumors (24), we used ABCG2-deficient KB1P tumors from K14cre;Brca1<sup>F/F</sup>;p53<sup>F/F</sup>;Abcg2<sup>−/−</sup> mice for these experiments.
experiments. Indeed, we found that 53BP1 expression was absent in 3 out of 20
topotecan-resistant tumors, whereas 53BP1 was still fully present in the
corresponding tumors before treatment (Supplementary Fig. S8). This strongly
suggests that 53BP1 loss is not exclusively a mechanism of olaparib resistance, but
may also play a role in resistance to other commonly used anti-cancer agents.

Long-term PARP inhibition by AZD2461 suppresses the development of
resistance
To circumvent the development of PARPi resistance we investigated whether long-
term dosing of a PARPi would be capable of causing eradication or chronic
suppression of KB1P tumors. We have previously shown that long-term olaparib
treatment of 100 consecutive days significantly increased the overall survival of mice
with KB1P tumors compared to 28 days of treatment, but we also found that several
of these tumors acquired Pgp-mediated resistance (9). Therefore we tested the
response of KB1P tumors to the novel PARPi AZD2461 (Supplementary Fig. S9A),
which has lower affinity for Pgp than olaparib (13). Both AZD2461 and olaparib
completely inhibited the PARP activity for several hours and the amount of PAR
returned to baseline levels 24 hours after treatment (Supplementary Fig. S9B). 6
hours after drug administration we observed a small difference in PARP activity. This
may be caused by a higher potency of AZD2461 or a faster Pgp-mediated washout of
olaparib. We confirmed the low affinity of AZD2461 to Pgp by testing the inhibitor on
olaparib-resistant KB1P tumor T6-28, which has an 80-fold increased Mdr1b
expression (9). This tumor is sensitized to olaparib by pre-treatment with the Pgp
inhibitor tariquidar and it also responds well to AZD2461 without inhibition of Pgp
(Fig. 6A). In contrast, Pgp-deficient olaparib-resistant KB1PM tumors do not respond
to AZD2461 (Fig. 6B). These data show that AZD2461 is a novel PARPi with
potential to bypass Pgp-mediated resistance to olaparib.
We first studied short-term AZD2461 treatment in mice with KB1P tumors using daily
dosing for 28 consecutive days as we did for olaparib. Although mice treated with
AZD2461 clearly showed increased survival compared to olaparib-treated mice (p =
0.0061), all mice eventually developed relapsing tumors that were refractory to
PARPi treatment (Fig. 6C and Supplementary Fig. S9C). Three out of twelve
AZD2461-resistant KB1P tumors also showed loss of 53BP1 expression (Fig. 6D). In
the AZD2461-resistant tumor KB1P2 we found a deletion of 94 base pairs in exon 21
of Trp53bp1 (Fig. 6E and Supplementary Fig. S9D), which leads to a stop-codon
in this exon. We also identified a deletion of 34 base pairs on the boundary of intron
24 and exon 25 of Trp53bp1 in AZD2461-resistant tumor KB1P8 (Fig. 6F and
Supplementary Fig. S9E).

When we increased the AZD2461 treatment to 100 consecutive days, we found that
8 out of 9 mice engrafted with fragments from 3 individual KB1P tumors did not
develop refractory tumors within 300 days after treatment start (Fig. 7A and
Supplementary Fig. S10A-C). In contrast, 6 out of 7 KB1P tumor-bearing mice
that received 100 days of consecutive olaparib treatment acquired drug resistance in
this time (Fig. 7A and Rottenberg et al. (9)). The tumor that acquired AZD2461
resistance during the first treatment cycle had an epithelial-to-mesenchymal
transition (EMT) phenotype (Supplementary Fig. S10D), which is frequently linked
to drug resistance (25).

Long-term AZD2461 treatment was well tolerated and doubled the median relapse-
free survival from 64 days to 132 days (p < 0.0001, Fig. 7B). Intriguingly, long-
term AZD2461 treatment did not result in tumor eradication: although tumor
remnants were not palpable during AZD2461 treatment, we found tumor relapse
once treatment was stopped on day 100 (Supplementary Fig. S10A-C).
Nevertheless, KB1P tumor recurrences were still sensitive when AZD2461 treatment
was resumed.
Discussion

Despite the induction of synthetic lethality of BRCA1-deficient cells by PARP inhibition (1;2), a heterogeneous response of breast or ovarian cancer patients who carry a BRCA1 mutation has been observed recently (4;10). This shows that there is an urgent need to identify mechanisms that thwart the success of this promising therapeutic approach. We have studied PARPi resistance using a mouse model for BRCA1-deleted breast cancer in which two known mechanisms, BRCA1 re-expression by genetic reversion and increased drug efflux by P-glycoprotein, were eliminated by genetic engineering. We show that loss of 53BP1 causes resistance to PARP inhibition in BRCA1-deficient mouse mammary tumors. As underlying mechanism, 53BP1-deficient KB1PM cells appear to have partially restored HR-mediated DNA repair, as evidenced by the presence of DNA damage-induced RAD51 foci. Hence, our data demonstrate that HR restoration by 53BP1 loss is a relevant drug resistance mechanism that occurs in real tumors.

Our results are consistent with recent in vitro data from the group of A. Nussenzweig (23) and our own group (22) showing that 53BP1 loss in BRCA1-deficient cells increases resistance to DNA-damaging agents and partially restores HR activity. While the underlying mechanisms are still under investigation, data from in vitro studies show that 53BP1 loss promotes end resection of DNA DSBs in the absence of BRCA1, resulting in RAD51 recruitment and subsequent HR (23). The importance of end resection for promoting HR over NHEJ has been shown earlier (26-28).

Loss of 53BP1 adds a novel in vivo mechanism of PARPi resistance to two other resistance mechanisms that have previously been identified in preclinical models: restoration of BRCA function (16;17;19) and increased Mdr1 gene expression (9). To what extent these mechanisms contribute to PARPi resistance in patients is still
unclear, although secondary somatic mutations restoring BRCA1/2 function have
been found in platinum resistant hereditary ovarian cancers (18). Interestingly,
53BP1 expression is frequently absent in BRCA1/2-mutated or triple negative breast
cancers (22). We therefore hypothesize that the poor overall survival of patients with
53BP1-negative breast cancer (22) is partly due to increased resistance to DNA-
damaging agents. It would therefore be useful to evaluate the utility of 53BP1 as a
biomarker for predicting response of BRCA1-deficient cancers to PARPi therapy.

HR restoration due to 53BP1 loss induces not only resistance to PARPi, but also to
the topoisomerase I inhibitor topotecan. In contrast, olaparib-resistant tumors were
still sensitive to the DNA cross-linking agent cisplatin or the topoisomerase II
inhibitor doxorubicin. Topotecan promotes SSBs which are converted into more
cytotoxic DSBs during DNA replication. It is therefore conceivable that partial HR
restoration is sufficient to antagonize this effect. Moreover, the topotecan cross-
resistance suggests that PARP inhibition primarily targets SSB repair (29).
Despite the remarkable capability of 53BP1-deficient cells to carry out homology-
directed DNA repair in the absence of BRCA1, our data suggest that this restoration
is not complete: the number of RAD51 IRIF-positive 53BP1-deficient KB1P(M) tumor
cells does not reach the level observed in 53BP1- and BRCA1-proficient KP tumor
cells in vitro. The fact that we observe more heterogeneous levels of RAD51 foci
using the short-term cell cultures of tumor cell suspensions may be due to the more
complex nature of this assay. Several factors in the procedure of tumor cell
dissociation and subsequent adhesion to cover slips may have an impact on RAD51
foci quantification.
We have previously reported that the amount of DNA damage inflicted by olaparib is
not sudden, but accumulates over a short period of time (9). As a result of this,
tumors only shrink after a few days of PARP inhibition, which correlates with a peak
of pH2AX foci about a week after the start of treatment. In contrast, the number of
pH2AX foci is much higher shortly after cisplatin treatment (data not shown). Hence,
partial restoration of HR by 53BP1 loss may not be sufficient for BRCA1-deficient
tumor cells to cope with the profound and acute induction of DNA damage by
cisplatin. This lack of complete cross-resistance is consistent with the recent in
findings of Bunting et al. (30): the absence of 53BP1 in Brca1<sup>A11/A11</sup> MEFs does not
rescue the hypersensitivity to cisplatin, in contrast to the sensitivity to PARP
inhibition. BRCA1 has also functions in the ICL repair that are not directly linked to
the HR pathway, such as replication fork protection (31) or recruitment of FANCD2
(30;32;33). It is likely that such additional functions explain the partial sensitivity to
cisplatin of our 53BP1- and BRCA1-deficient tumors.

The fact that 53BP1 loss only occurs in a fraction of the PARPi resistant mouse
mammary tumors indicates that other resistance mechanisms should exist in 53BP1-
positive tumors. These mechanisms might include impaired recruitment of 53BP1 to
sites of DNA damage due to dysfunctional recruitment factors, such as RNF8 or
RNF168, or prevention of PARPi-induced DNA damage through inhibition of other
NHEJ-associated factors (34). We found at least two PARPi resistant tumors (KB1PM3
and 9) in which both RAD51 and 53BP1 IRIFs are formed (Fig. 4C and
Supplementary Fig. S6). This strongly suggests a 53BP1-independent mechanism
of HR restoration in BRCA1-deficient cells. In addition, the lack of RAD51 IRIF
formation in olaparib-resistant KB1PM1 suggests an HR-independent resistance
mechanism. We are currently investigating what other mechanism may explain this
outcome by using functional screens in our panel of BRCA1-deficient cell lines.
The observation that in several PARPi-resistant tumors 53BP1 expression is lost in
only a fraction of tumor cells strongly suggests that different resistance mechanisms
may be selected within an individual tumor. Distinct clonal subpopulations and their
relation to metastasis were recently characterized in breast cancer (35). Our data suggest that distinct subpopulations of tumor cells utilizing different resistance mechanisms may evolve during PARPi treatment. This heterogeneity might complicate the design of novel therapeutic strategies to reverse PARPi resistance. Our model may be a useful tool to test such therapeutic approaches before they enter clinical trials.

As one strategy to minimize the risk of development of PARPi resistance we present continuous treatment with the novel PARPi AZD2461. Whereas 28-day treatment with AZD2461 resulted in induction of resistance (which was in several tumors mediated by 53BP1 loss), chronic treatment resulted in complete remission and suppression of refractory disease during a period of 300 days. Although chronic AZD2461 treatment did not result in tumor eradication, it inhibited the outgrowth of drug resistant clones. Apparently, the pool of proliferating cells, in which new mutations can arise, is effectively reduced in size. While we cannot exclude that resistance to AZD2461 may develop at later time points, our data suggest that chronic PARP inhibition may be a promising strategy to achieve long-term tumor suppression in patients with HR-deficient tumors. Other PARPi’s that are not Pgp substrates, such as veliparib (ABT888) (36), might have the same potential. In case Pgp-mediated olaparib resistance does not occur in humans, stable disease suppression might also be achieved using olaparib. In fact, in a phase II study, maintenance therapy using olaparib prolonged progression-free survival of patients with high-grade serous ovarian carcinoma (37). Of note, benefit from long-term PARPi treatment may not be restricted to BRCA-mutation carriers, as 51% of the high-grade serous ovarian carcinomas were found to have a genetic or epigenetic alteration in the HR pathway and may therefore respond to PARPi (38).
Collectively, our results further the understanding of PARPi resistance and underscore the relevance of HR restoration in BRCA1-deficient mammary tumors that cannot escape treatment by increased drug efflux, restoration of BRCA1 function or residual activity of the BRCA1 mutant protein (15). Moreover, we show how preclinical evaluation of targeted therapeutics in genetically engineered mice can facilitate the development of therapeutic strategies that may prolong the treatment benefit in cancer patients.
Methods

Mice, generation of mammary tumors and orthotopic transplantations

Brca1Δ/Δ;p53Δ/Δ mammary tumors were generated in K14cre;Brca1F/F;p53F/F (KB1P) female mice and genotyped as described previously (11). In this study we used KB1P mice that were back-crossed to a pure FVB/N background. To generate Brca1Δ/Δ;p53Δ/Δ;Mdr1a/b−/− tumors we crossed Mdr1a/b−/− mice (20;21) with KB1P mice to produce K14cre;Brca1F/F;p53F/F;Mdr1a/b−/− (KB1PM) mice. Mdr1a and Mdr1b genotypes were tested by PCR with specific primers (Mdr1a forward: 5’-GTGCATAGACCACCCTCAAGG-3’; Mdr1b forward: 5’-AAGCTGTGCATGATTCTGGG-3’) for wild type (Mdr1a reverse: 5’-GTCATGCACATCAAACCAGCC-3’; Mdr1b reverse: 5’-GAGAAACGATGTCCTTCCAG-3’) and deleted alleles (Mdr1a reverse: 5’-GGAGCAAAGCTGCTATTGGC-3’). Orthotopic transplantations into wild-type FVB/N mice, tumor monitoring and sampling were performed as described (12). For the transplantation of cell lines 500,000 cells in PBS and matrigel (1:1) were injected in the fourth right mammary fat pad. All experimental procedures on animals were approved by the Animal Ethics Committee of the Netherlands Cancer Institute.

Drugs and treatment of tumor-bearing mice

Starting from two weeks after transplantation tumor size was monitored at least three times a week. All treatments were started when tumors reached a size of ≈200 mm³. Olaparib (50 mg/kg i.p.) and AZD2461 (100 mg/kg p.o.) were given for 28 consecutive days, unless otherwise indicated. If tumors did not shrink below 50 % of the initial volume, treatment was continued for another 28 days; otherwise a new treatment cycle of 28 days was started when the relapsing tumor reached a size of 100% of the original volume (except for Figure 5E, where only one 28-day cycle of olaparib treatment was used). AZD2461 was diluted in 0.5 % w/v HPMC in deionized water.
water to a concentration of 10 mg/ml. The synthesis of AZD2461 is described in international patent WO2009/093032, specifically compound numbers 2b and 47. For testing cross-resistance, mice were treated with a single treatment regimen of topotecan (2 mg/kg i.p., days 0-4 and 14-18), cisplatin (Mayne Pharma, 6 mg/kg i.v., day 0) or doxorubicin (Amersham Pharmacia Netherlands, 5 mg/kg i.v., day 0, 7 and 14). Tariquidar (Avaant, 2 mg/kg i.p.) was administered 15 minutes prior to the olaparib injection for 28 consecutive days. Tumor volume was calculated with the following formula: \( V = \frac{l \times b^2}{2} \).

**PAR Immunoassay**

The ELISA for detecting poly-ADP-ribose was described before (39). In brief, tissue lysates are prepared in Cell Extraction Buffer (Invitrogen, FNN0011) supplemented with 1x protease inhibitor cocktail (Sigma-Aldrich P-2714 or Roche 11697498001) and 2 mM PMSF (Sigma-Aldrich, Cat#: 93482-50ML-F). Protein concentration is determined with BCA Protein Assay Kit (Thermo Scientific Pierce, Cat#: 23227 or 23225). PAR standards are prepared from pure PAR (BioMol International, Plymouth Meeting, PA, SW-311) and diluted in Superblock (Pierce 37535). Pierce Reactibind (15042) plates were coated with Trevigen Monoclonal anti-PAR (4335) diluted to a concentration of 4 \( \mu \)g/ml in pH 9.6 carbonate buffer, overnight at 4 °C and washed with PBS-0.1 % Tween (Sigma-Aldrich). Blocking was performed with Superblock at 37 °C for one hour. Samples, standards and controls were incubated in the plate for 16 hours at 4 °C. After washing 4 times, rabbit anti-PAR (Trevigen 4336, 1:500 in PBS-2 % BSA-1 % mouse serum) was incubated at 25 °C for 2 hours. Goat-anti-rabbit-HRP (KPL Inc., Gaithersburg, MD, 074-15-061, 1 µg/ml in PBS-2 % BSA-1 % mouse serum) was incubated at 25 °C for 1 hour. Detection was performed with Supersignal Pico Chemiluminescent Substrate (Pierce 37070) and plates were read on a Tecan Infinite or Tecan Genios Pro Luminometer (Tecan; Mannedorf,
Switzerland). Detailed descriptions of the sample preparation and the protocol are available online (40;41).

**Immunohistochemistry**

For immunohistochemical stainings antigen retrieval was done by cooking in citrate buffer pH 6.0 (53BP1 and γH2AX) or proteinase K digestion (vimentin). Furthermore, the stainings were carried out by using 3 % H$_2$O$_2$ for blocking endogenous peroxidase activity, 5 % goat serum plus 2.5 % bovine serum albumin (BSA) in phosphate buffered saline (PBS) as blocking buffer and antibody diluent, overnight first-antibody incubation and one hour incubation with the secondary antibody. For detection we used streptavidin-HRP (Dako K1016, 10 minutes incubation at room temperature), DAB (Dako K3468) and haematoxylin counterstaining.

**Immunoblotting**

Cells were harvested by trypsinisation, washed in PBS, lysed in RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 % Nonidet-P40, 0.1 % SDS, 0.5 % Na-deoxycholate and 25x Complete protease inhibitor cocktail (Roche)), incubated on ice and sonicated. Equal amounts of protein were run on NuPAGE Novex Tris-Acetate 3-8 % (w/v) (Invitrogen) according to manufacturer’s instructions, followed by Western blotting.

**DNA damage-induced foci detection**

Cryopreserved tumor pieces were digested with 3 mg/ml collagenase A and 0.1 % trypsin for two hours at 37 °C, filtered, seeded on coverslips and irradiated with 10 Gy after 48 hours. Cell lines were grown on coverslips for 16-24 hours before irradiation. Cells were fixed 6 hours after irradiation in 2 % paraformaldehyde in PBS++ (with 1mM CaCl$_2$ and 0.5 mM MgCl$_2$). Cells were permeabilized in 0.2 %
Triton-X100/PBS++ for 20 minutes and incubated in staining buffer (1 % BSA, 0.15 % glycin and 0.1 % Triton-X100 in PBS++) for 30 minutes at room temperature. The staining buffer was used for all washing steps and as solvent for antibodies. Incubation with primary and secondary antibodies was done for 2 hours and 1 hour respectively at room temperature. DNA was stained with To-Pro-3 (Molecular Probes, 1:2000). Images were taken with a Leica TCS SP2 (Leica Microsystems, Heidelberg, Germany) confocal system, equipped with an Ar Diode 561 and HeNe 633 laser system. Images were taken using a 63x NA 1.32 objective. Standard LCS software was used for processing. RAD51 foci were quantified by counting them in the maximum projection of z-images. At least 100 cells were counted blindly on four different fields per slide and every cell line has been measured in two independent experiments.

Antibodies

All antibodies and their dilutions are summarized in Supplementary Table S1.

Establishment and maintenance of tumor cell lines

Tumors were harvested, minced and digested in RPMI 1640 (Gibco) supplemented with 2 % FBS (Sigma), 3 mg/ml collagenase A and 0.1 % trypsin (Gibco) for 30 minutes at 37 °C. Cells were passed through a 40 μm cell strainer (Falcon), washed three times and seeded in DMEM/F12 (Gibco) supplemented with 20 ng/mL bFGF (Invitrogen), 20 ng/mL EGF (Invitrogen), B-27 supplement (1:50 dilution, Invitrogen) and 4 μg/mL heparin on ultra-low attachment plates (Corning Incorporated) to grow them as mammospheres. Established mammospheres were plated in cluster plates in DMEM/F12 culture medium (with 10 % FBS, 5 % penicillin/streptomycin (Gibco), 5 μg/ml insulin (Sigma), 5 ng/ml EGF (Invitrogen) and 5 ng/ml cholera toxin (Sigma)) under low oxygen (3 %) conditions to obtain.
epithelial cell populations. All mammosphere-derived BRCA1-deficient cell lines were continuously cultured under low oxygen conditions.

**Trp53bp1 knock down**

*Brca1Δ/Δ; p53Δ/Δ* cell lines (KB1P-B11 and KB1P-G3) were transduced with lentiviral pLKO.1-puro vectors containing non-targeting shRNA (Sigma SHC002) or one of the *Trp53bp1*-targeting hairpins (TRCN0000081778 and TRCN0000081781) from the Sigma MISSION library. Infected cells were selected by growth in medium containing 2 µg/ml (B11) or 3 µg/ml (G3) puromycin for two weeks.

**Reconstitution of Trp53bp1**

For transfection of pCMH6K-*Trp53bp1* (a gift from K. Iwabuchi, Kanazawa Medical University, Ishikawa, Japan) 1 µg DNA in DMEM was used with lipofectamine reagent (Invitrogen) according to the manufacturers’ instruction. After 18-24 hours the medium was replaced by complete medium. Hygromycin B (100 µg/ml) was added to the growing cells for 4 days.

**Mutation analysis**

Genomic DNA was isolated from frozen tumor pieces and cell pellets with phenol/chloroform and isopropanol precipitation. RNA was extracted from tumor pieces with trizol and isopropanol precipitation and from cell pellets with the High pure RNA isolation kit (Roche 11828665001). cDNA was prepared using the First strand synthesis system (Invitrogen 18080-051). For sequencing we used the Big Dye Terminator v3.1 cycle sequencing kit (Applied Biosystems). Primers that were used to detect the rearrangement in KB1PM5 and the mutations in KB1PM8, KB1P2 and KB1P8 are depicted in **Supplementary Table S2**.
**Clonogenic assay**

To measure the effect of olaparib on the colony-forming capacity we seeded cells at low density in 6-well plates. The next day olaparib was added and the concentration of dimethylsulfoxide (DMSO) was equalized for every well. After seven days the colonies are fixed and stained with Leishman’s eosin methylene blue solution (Merck 105387). All concentrations are measured in duplo and each experiment is done three times.

**Array Comparative Genomic Hybridization (aCGH)**

Genomic DNA was extracted with proteinase K and phenol-chloroform, fragmented and labeled with the Klenow kit (Roche). Tumor and spleen samples were labeled with the Nimblegen dual-color DNA labeling kit and hybridized to Nimblegen 12-plex 135K full genome mouse custom NKI array. The data are analyzed with NimbleScan software.
Acknowledgements

We would like to thank Anton Berns and Peter Bouwman for critical reading of the manuscript; Susan Bates from the National Institutes of Health, Bethesda, MD, for providing tariquidar; and Thijs Siegenbeek van Heukelom and Marieke Haenen for technical support.
Grant support

This work was supported by grants from the Netherlands Organization for Scientific Research (NWO-Toptalent 021.002.104 to J.E.J. and NWO-VIDI-91711302 to S.R.); the Dutch Cancer Society (projects NKI 2006-3566, NKI 2007-3772, NKI 2009-4303, and NKI 2011-5220); the European Union (EU) FP6 Integrated Project 037665-CHEMORES; the EU FP7 Project 260791-EurocanPlatform; CTMM Breast Care; and the NKI-AVL Cancer Systems Biology Centre.


(8) Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phth
Alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.


Ref Type: Unpublished Work

BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for

Resistance to therapy caused by intragenic deletion in BRCA2. Nature

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-

(18) Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W et al. Secondary
Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in

(19) Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary
BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum

Normal viability and altered pharmacokinetics in mice lacking mdr1-type
(drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 1997;94:4028-
33.

(21) Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter
L et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a
deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell

(22) Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H et
al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative


(29) Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings. Mol Oncol 2011.


**Figure legends**

**Figure 1.** Acquired resistance of P-glycoprotein-deficient Brca1Δ/Δ; p53Δ/Δ (KB1P) mouse mammary tumors to the PARPi olaparib. **A,** Kaplan-Meier curve showing survival of mice bearing Pgp-proficient KB1P or Pgp-deficient KB1PM tumors, either untreated or treated with 50 mg olaparib per kg i.p. for 28 consecutive days. Treatment was resumed when a relapsing tumor reached a size of 100% (the tumor size at the start of the treatment). Individual tumor responses are shown in **Supplementary Fig. S1.** The Gehan-Breslow-Wilcoxon p-value is indicated. **B,** response to daily treatment with 50 mg olaparib per kg i.p. of olaparib-resistant tumors from three donor tumors (KB1PM1, 3 and 4) and drug-naive control tumors from the corresponding donors. **C,** levels of poly(ADP-ribose) (PAR) detected in whole tumor extracts from olaparib-resistant and control tumors derived from KB1PM1, 3 and 4. The tumors were harvested either without treatment, 30 minutes after one dose of 50 mg olaparib per kg i.p. or 2 hours after the last dose of 7 days of daily treatment. n.d. = not detectable (lower than 2*SD above background). Data are presented as mean+SD of three mice per donor per treatment.

**Figure 2.** Response of olaparib-resistant tumors to DNA-damaging agents. **A,** classification of the response of olaparib-resistant and control tumors from five individual donors (KB1PM1, 3, 4, 5 and 8) to olaparib (50 mg/kg, daily for 28 days), topotecan (2 mg/kg, day 0-4 and 14-18), cisplatin (6 mg/kg, day 0) and doxorubicin (5 mg/kg, day 0, 7 and 14). Untreated tumors would be classified as 'poor responders'. **B-D,** for the same group of mice the relapse-free survival is shown in response to topotecan, cisplatin or doxorubicin. The poor and intermediate responders of figure **A** have a relapse-free survival of 0 days since the tumor did not
shrink below 50% of the original size. Day 0 is the start of the treatment. The Gehan-Breslow-Wilcoxon p-values are indicated.

**Figure 3.** Loss of 53BP1 protein in olaparib-resistant tumors. **A,** 53BP1 in control and olaparib-resistant KB1PM tumors. Depicted are two individual tumors with loss of 53BP1 and one of the olaparib-resistant tumors that still express 53BP1. The 53BP1-positive cells in the resistant tumors of KB1PM5 and 8 are either stroma or a duct from the wild-type host mammary gland. **B,** olaparib-resistant tumor KB1PM3 shows focal loss of 53BP1 expression. **C,** cDNA sequencing revealed a duplication of exons 25 and 26 in 53BP1 resulting in a frame shift and premature stop codon in the olaparib-resistant tumor cells of KB1PM5. The alternating codons are underlined and the premature stop codon is indicated in bold. **D,** identification of a heterozygous truncating mutation Q626* in exon 12 in the 53BP1-negative areas of olaparib-resistant tumor KB1PM8. cDNA sequencing identified only the mutated allele. Primers that were used for KB1PM5 and KB1PM8 are listed in **Supplementary Table S2.** Scale bar = 100 μm.

**Figure 4.** DNA damage foci in irradiated cells. **A,** detection of ionizing radiation-induced RAD51, 53BP1 and γ-H2AX foci in BRCA1-proficient KP3.33 cells (5), a cell line derived from a KB1PM5 control tumor (control 1), and a 53BP1-negative cell line derived from the olaparib-resistant KB1PM5 tumor (ol-res 1). For characterization of the cell lines, see also **Supplementary Fig. S5.** Images show the maximum projection, covering the whole cell in the z-direction. **B,** quantification of RAD51 focus formation of three KB1PM5 control cell lines and three KB1PM5 olaparib-resistant cell lines in two independent experiments. The three control cell lines are combined in one bar and each olaparib-resistant cell line is shown separately for both experiments. **C,** quantification of RAD51 IRIFs in a control KP tumor and in matched
olaparib-sensitive and -resistant KB1PM tumors. See also Supplementary Figure S6. IR = ionizing radiation.

**Figure 5.** The effect of 53BP1 loss on olaparib sensitivity. **A,** Western blot showing 53BP1 levels in KB1P-B11 and KB1P-G3 cells that express a non-targeting hairpin (NT) or a hairpin against Trp53bp1. **B,** clonogenic assay with olaparib. The IC50 is indicated between brackets. **C,** Western blot showing the reconstitution of 53BP1 in 53BP1-deficient KB1P-3.12 cells. KP cells are used as positive control for the BRCA1 western blot. **D,** clonogenic assay of 53BP1-negative KB1P-3.12 cells, h53BP1-reconstituted KB1P-3.12 cells and BRCA-proficient KP cells. **E,** overall survival of mice with a 53BP1-positive (shNT) or –negative (sh53BP1) tumor treated with one regimen of olaparib daily for 28 days and the untreated control mice. 53BP1 expression in these tumors is shown in Supplementary Fig. S7C. **F,** Relapse-free survival of mice with a 53BP1-positive (shNT) or –negative (sh53BP1) tumor treated with one dose of cisplatin. The Gehan-Breslow-Wilcoxon p-values are indicated.

**Figure 6.** Non-Pgp-mediated resistance to the next-generation PARP inhibitor AZD2461. **A,** overall survival of mice with an olaparib-resistant KB1P tumor with 80-fold increase in Mdr1b expression, that were treated with the vehicle of AZD2461 (0.5 % v/w HPMC), olaparib, olaparib in combination with the Pgp-inhibitor tariquidar or with AZD2461. **B,** tumor response of the olaparib-resistant and control tumor from the Pgp-deficient KB1PM tumors 1, 3 and 4 to AZD2461. **C,** Kaplan-Meier curve showing survival of mice with a Pgp-proficient KB1P tumor, either untreated or after treatment with olaparib or AZD2461. Individual tumor responses are shown in Supplementary Figs. S1C and S9C. The Gehan-Breslow-Wilcoxon p-value is indicated. **D,** 53BP1 in control and AZD2461-resistant KB1P tumors. Depicted are three individual tumors with loss of 53BP1 and one of the AZD2461-resistant tumors.
that still express 53BP1. Scale bar = 100 μm. 

E, identification of a 94bp deletion in exon 21 of Trp53bp1 in AZD2461-resistant tumor KB1P2, leading to a frame shift and early stop codon in exon 21. 

F, identification of a 34bp deletion at the splice acceptor site of exon 25 of Trp53bp1.

Figure 7. Chronic anti-tumor efficacy of the novel PARP inhibitor AZD2461. 

A, overall survival of mice receiving 100 days of olaparib (see also (9)) or AZD2461 treatment. After relapse of a tumor to a size of 100 % another 100 days of treatment was given. Individual tumor responses are shown in Supplementary Fig. 

S10A-C. B, relapse-free survival of mice with a KB1P tumor that received AZD2461 for 28 consecutive days or for 100 consecutive days. The Gehan-Breslow-Wilcoxon p-values are indicated.
Figure 1. Acquired resistance of P-glycoprotein-deficient \textit{Brca1}\textsuperscript{Δ/Δ};\textit{p53}\textsuperscript{Δ/Δ} (KB1PM) mouse mammary tumors to the PARP inhibitor olaparib.

\textbf{A}

\begin{figure}[h!]
\centering
\includegraphics[width=\textwidth]{figure1a.png}
\end{figure}

\textbf{B}

\begin{figure}[h!]
\centering
\includegraphics[width=\textwidth]{figure1b.png}
\end{figure}

\textbf{C}

\begin{figure}[h!]
\centering
\includegraphics[width=\textwidth]{figure1c.png}
\end{figure}
Figure 2: Response of olaparib-resistant tumors to DNA-damaging agents.

A

B

cisplatin

doxorubicin

topotecan

Good response (shrinkage <50%)
Intermediate response (no shrinkage <50%, at day 14 <1000mm³)
Poor response (no shrinkage <50%, at day 14 >1000mm³)

control (n=15)

olaparib-resistant (n=15)

p = 0.003

control (n=15)

olaparib-resistant (n=19)

p = 0.0167

control (n=13)

olaparib-resistant (n=15)

p = 0.0172

relapse-free survival (%) vs time (days)
Figure 3. Loss of 53BP1 protein in olaparib-resistant tumors.

A

untreated

olaparib-resistant

B

KB1PM3

C

KB1PM5
untreated

KB1PM5
olaparib-resistant

EXON 26...CAACGAATTCTGGAATTTTGTTAGAAGATTTCTGCC...EXON 25

D

KB1PM8
untreated

KB1PM8
ol-res

FFPE-extracted genomic DNA

cDNA

KB1PM8
ol-res
Figure 4. DNA damage foci in irradiated cells.

A

<table>
<thead>
<tr>
<th></th>
<th>IR</th>
<th>RAD51</th>
<th>53BP1</th>
<th>γH2AX</th>
</tr>
</thead>
<tbody>
<tr>
<td>KP3.33</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>KB1PM5 control 1</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>KB1PM5 ol-res 1</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

B

![Graph showing the percentage of cells with ≥10 RAD51 foci](image)

C

![Graph showing the percentage of cells with ≥10 RAD51 foci](image)
Figure 5. The effect of 53BP1 loss on olaparib sensitivity.

A

<table>
<thead>
<tr>
<th>B11</th>
<th>G3</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

53BP1

B

- B11 shNT (11 nM)
- B11 sh53BP1 #1 (10 nM)
- B11 sh53BP1 #2 (32 nM)

- G3 shNT (8 nM)
- G3 sh53BP1 #1 (155 nM)
- G3 sh53BP1 #2 (76 nM)

C

- BRCA1
- 53BP1
- Anti-HA
- ACTIN

D

- KD17-B11 shNT - untreated (%10)
- KB1P-B11 shNT - olaparib (%10)
- KD17-B11 sh53BP1 #1 - untreated (%10)
- KB1P-B11 sh53BP1 #1 - olaparib (%11)

E

- KB1P-B11 shNT - ciplatin (%8)
- KB1P-B11 sh53BP1 #1 - ciplatin (%9)

F

- KB1P-B11 shNT - ciplatin (%8)
- KB1P-B11 sh53BP1 #1 - ciplatin (%9)
Figure 6. Non-Pgp-mediated resistance to the next-generation PARP inhibitor AZD2461.

A

B

c

D

E

F
Figure 7. Chronic anti-tumor efficacy of the novel PARP inhibitor AZD2461.

A

B

Downloaded from cancerdiscovery.aacrjournals.org on June 19, 2017. © 2012 American Association for Cancer Research.
Loss of 53BP1 causes PARP inhibitor resistance in BRCA1-mutated mouse mammary tumors
Janneke E. Jaspers, Ariena Kersbergen, Ute Boon, et al.
Cancer Discovery Published OnlineFirst October 25, 2012.

Updated version
Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-12-0049

Supplementary Material
Access the most recent supplemental material at: http://cancerdiscovery.aacrjournals.org/content/suppl/2012/10/25/2159-8290.CD-12-0049.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.